{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:38:42Z","timestamp":1793831922916,"version":"4.6.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"24","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Incorporated"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Aficamten is a next-in-class, oral selective cardiac myosin inhibitor that ameliorates hypercontractility in hypertrophic cardiomyopathy (HCM). This study assessed the safety and efficacy of extended aficamten treatment in symptomatic obstructive HCM (oHCM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients completing a parent aficamten study were eligible to enrol in FOREST-HCM (NCT04848506), an open-label study evaluating long-term aficamten treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with oHCM (N = 296; mean age \u00b1SD 61 \u00b1 12.3 years, 44.3% female) enrolled between May 2021 and August 2024. Cumulative exposure was 352 patient-years; median follow-up 51.6 (IQR 41.5, 70.8) weeks. At Weeks 12 and 96, aficamten reduced Valsalva left ventricular outflow tract gradient by 56 \u00b1 43 and 62 \u00b1 33 mmHg from baseline (both P &amp;lt; 0.0001), with minimal reduction in left ventricular ejection fraction (LVEF) (\u22123% \u00b1 6% and \u22125% \u00b1 5%); 69% and 93% of participants had at least one NYHA class improvement; Kansas City Cardiomyopathy Questionnaire\u2013Clinical Summary Score improved by 15 \u00b1 16 and 16 \u00b1 16 points. Treatment-emergent serious adverse events (TESAEs) occurred in 36 (12.2%) patients; no deaths, heart failure, or events considered related to aficamten were reported. One (0.3%) patient terminated therapy due to a TESAE (ischemic colitis). LVEF&amp;lt;50% occurred in 10 (3.4%) patients [exposure-adjusted incidence rate (EAIR): 2.9 per 100 patient-years] with 2 having non-serious mild\/moderate dyspnoea. No treatment interruptions for LVEF&amp;lt;50%, and no events of LVEF&amp;lt;40% occurred. New-onset atrial fibrillation occurred in seven (2.4%) patients (EAIR 2.0 per 100 patient-years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Extended aficamten treatment in patients with symptomatic oHCM yielded early and sustained hemodynamic and clinical responses with low incidences of new-onset atrial fibrillation and LVEF&amp;lt;50%.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf1085","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:00:20Z","timestamp":1766581220000},"page":"3120-3131","source":"Crossref","is-referenced-by-count":5,"title":["Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study"],"prefix":"10.1093","volume":"47","author":[{"given":"Albree","family":"Tower-Rader","sequence":"first","affiliation":[{"name":"Cardiology Division, Department of Medicine, 55 Fruit St, Yawkey 5B, Massachusetts General Hospital , Boston, MA 02114 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Oregon Health and Science University , Portland, OR ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Nassif","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Missouri Kansas City Healthcare Institute for Innovations in Quality and Saint Luke\u2019s Mid America Heart Institute, Kansas City, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3411-1334","authenticated-orcid":false,"given":"Theodore P","family":"Abraham","sequence":"additional","affiliation":[{"name":"Divison of Cardiology, University of California San Francisco , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-3487","authenticated-orcid":false,"given":"Roberto","family":"Barriales-Villa","sequence":"additional","affiliation":[{"name":"Complexo Hospitalario Universitario A Coru\u00f1a, INIBIC, CIBERCV-ISCIII , A Coru\u00f1a ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Divison of Cardiology, Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Liverpool John Moores University , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M","family":"Elliott","sequence":"additional","affiliation":[{"name":"Barts Heart Centre, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S","family":"Maron","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Lahey Hospital and Medical Center , Burlington, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[{"name":"Meyer Children\u2019s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Oreziak","sequence":"additional","affiliation":[{"name":"1st Department of Arrhythmia, National Institute of Cardiology , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9669-8495","authenticated-orcid":false,"given":"Anjali Tiku","family":"Owens","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Heitner","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L","family":"Jacoby","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5469-1287","authenticated-orcid":false,"given":"Stuart","family":"Kupfer","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Liu","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady I","family":"Malik","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Melloni","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyrell J","family":"Simkins","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Wei","sequence":"additional","affiliation":[{"name":"Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Saberi","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"2026062219565105000_ehaf1085-B1","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"83","author":"Writing Committee Members","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026062219565105000_ehaf1085-B2","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026062219565105000_ehaf1085-B3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s0140-6736(95)91267-3","article-title":"Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy","volume":"346","author":"Sigwart","year":"1995","journal-title":"Lancet"},{"key":"2026062219565105000_ehaf1085-B4","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/s44161-024-00505-0","article-title":"Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy","volume":"3","author":"Hartman","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"2026062219565105000_ehaf1085-B5","doi-asserted-by":"publisher","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J Med Chem"},{"key":"2026062219565105000_ehaf1085-B6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026062219565105000_ehaf1085-B7","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"2026062219565105000_ehaf1085-B8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jchf.2024.11.011","article-title":"Aficamten vs metoprolol for obstructive hypertrophic cardiomyopathy: MAPLE-HCM rationale, study design, and baseline characteristics","volume":"13","author":"Garcia-Pavia","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026062219565105000_ehaf1085-B9","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/s0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026062219565105000_ehaf1085-B10","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026062219565105000_ehaf1085-B11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jchf.2022.03.002","article-title":"Validation of the Kansas City Cardiomyopathy Questionnaire in symptomatic obstructive hypertrophic cardiomyopathy","volume":"10","author":"Nassif","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026062219565105000_ehaf1085-B12","doi-asserted-by":"publisher","first-page":"102496","DOI":"10.1016\/j.jchf.2025.03.040","article-title":"Aficamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: 48-week results from FOREST-HCM","volume":"13","author":"Saberi","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026062219565105000_ehaf1085-B13","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"key":"2026062219565105000_ehaf1085-B14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","article-title":"Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003\u20132011","volume":"1","author":"Kim","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2026062219565105000_ehaf1085-B15","doi-asserted-by":"publisher","first-page":"e007673","DOI":"10.1161\/CIRCINTERVENTIONS.118.007673","article-title":"Guideline-based referral for septal reduction therapy in obstructive hypertrophic cardiomyopathy is associated with excellent clinical outcomes","volume":"12","author":"Kimmelstiel","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"2026062219565105000_ehaf1085-B16","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.124.069378","article-title":"Long-term outcomes after septal reduction therapies in obstructive hypertrophic cardiomyopathy: insights from the SHARE Registry","volume":"150","author":"Maurizi","year":"2024","journal-title":"Circulation"},{"key":"2026062219565105000_ehaf1085-B17","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"MAPLE-HCM Investigators. Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy","volume":"393","author":"Garcia-Pavia","year":"2025","journal-title":"N Engl J Med"},{"key":"2026062219565105000_ehaf1085-B18","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/hc4601.097997","article-title":"Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy","volume":"104","author":"Olivotto","year":"2001","journal-title":"Circulation"},{"key":"2026062219565105000_ehaf1085-B19","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.jacc.2024.08.002","article-title":"Impact of aficamten on echocardiographic cardiac structure and function in symptomatic obstructive hypertrophic cardiomyopathy","volume":"84","author":"Hegde","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026062219565105000_ehaf1085-B20","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.jacc.2024.08.015","article-title":"Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM CMR substudy","volume":"84","author":"Masri","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/24\/3120\/67228699\/ehaf1085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/24\/3120\/67228699\/ehaf1085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:57:00Z","timestamp":1782172620000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/24\/3120\/8505948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":20,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2026,3,5]]},"published-print":{"date-parts":[[2026,6,23]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf1085","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,21]]},"published":{"date-parts":[[2026,3,5]]}}}